US drugmaker Cosette Pharmaceuticals has entered into a definitive agreement to acquire all the outstanding shares of ...

Binnopharm Group, one of Russia’s leading drugmakers, which is controlled by the Russian financial conglomerate AFK Sistema, ...

US biopharma Incyte and privately-held AI-focused biotech Genesis Therapeutics have entered into a strategic collaboration ...

Just days after Robert F Kennedy Jr's (RFK Jr) nomination to lead the US Department of Health and Human Services (HHS) was ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance ...

Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...

South Korean biosimilars developer Celltrion late yesterday announced new post-hoc analyses of its pivotal LIBERTY studies ...

Japan's Ministry of Health, Labor and Welfare (MHLW) has granted manufacturing and marketing approval for Andembry ...

French biotech tart-up EG 427 has successfully closed a 27 million-euro ($28.4 million) Series B financing round co-led by ...

Once the hottest property in biotech, gene therapy company bluebird bio has been sold for less than $500 million after a long series of setbacks.

Privately-held Austria firm pharmaand GmbH (pharma&) today announced that the National Institute of Health and Care Excellence (NICE) has issued a positive recommendation for its Rubraca (rucaparib).

US healthcare giant Johnson & Johnson has announced data from the Phase III ASTRO study of Tremfya (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ...